Where to Apply for MS Drug Copay Assistance in 2020

Each year, MS patients can apply for copay assistance from a number of resources. These programs are needs-based but income cutoff is very generous. For example, patients whose income is as high as 400 percent above the Federal Poverty Level will qualify for assistance. To determine whether you might be eligible, see the Federal Poverty Level table below.

2020 Federal Poverty Guidelines

Persons in family/householdPoverty guideline
1$12,760
2$17,240
3$21,720
4$26,200
5$30,680
6$35,160
7$39,640
8$44,120

Source: Office of the Assistant Secretary for Planning and Evaluation

To calculate your eligibility: Take the income level on the chart that matches the size of your household and multiply it by 4.0 to see what is 400 percent of that income. For example, if you live in a one-person household then you can make as much as $49,960 and still qualify for assistance.

Most drug companies offer a patient assistance program that will cover all or the majority of MS drugs’ high copays. With some exceptions, they will only consider patients who have commercial insurance.

Below is the contact information for the drug company copay assistance program that manufactures MS DMDs and symptom medications.

Disease-modifying drugs

Avonex, Plegridy, Tecfidera, Tysabri, and Vumerity:
Biogen
1-800-456-2255
www.abovems.com

Aubagio:
Genzyme, a Sanofi company
1-855-676-6326
www.MSOnetoOne.com

Betaseron:
Bayer Healthcare Pharmaceuticals, Inc.
1-800-788-1467
www.betaseron.com

Copaxone:
Teva Neuroscience
1-800-887-8100
www.sharedsolutions.com

Extavia:
Novartis Pharmaceutical Corp.
1-866-398-2842
www.extavia.com

Gilenya:
Novartis Pharmaceutical Corp.
1-800-GILENYA (1-800-445-3692)
www.gilenya.com

Glatiramer Acetate Injection:
Mylan
1-844-695-2667

Glatopa (generic equivalent of Copaxone 20mg)
Sandoz
1-855-452-8672
www.glatopa.com

Lemtrada:
Genzyme, a Sanofi company
1-855-676-6326
www.lemtrada.com

Mavenclad
EMD Serono, Inc., and Pfizer, Inc.
1-877-447-3243
www.mavenclad.com

Mayzent
Novartis Pharmaceutical Corp.
1-800-277-2254
www.mayzent.com

Novantrone
No patient assistance programs available at this time.

Ocrevus:
Genentech
1-844-627-3887
www.genentech-access.com

Rebif:
EMD Serono, Inc. and Pfizer, Inc.
1-877-447-3243
www.mslifelines.com

Symptom medications

Dalfampridine (formerly Ampyra) — for walking faster:
Acorda Therapeutics
1-888-881-1918
www.ampyra.com

Botox — for bladder dysfunction and spasticity in upper/lower limbs:
Allergan, Inc.
www.botox.com

H.P. Acthar (Repository Corticotropin) — for acute MS exacerbations:
Questcor Pharmaceuticals, Inc.
1-888-435-2284
www.actharmsrelapse.com

*If you don’t see your DMD or symptom medication listed, check contact info provided by the National Multiple Sclerosis Society here.

Infusion center locator

National Infusion Center Association offers an online infusion center finder (US only) that locates facilities that administer both IV and injectable medications.

Private charity organizations for those with government insurance

Several private charities cover copays for those that are insured and those who have only Medicare or Medicaid:

Patient Access Network Foundation (PAN):  1-866-316-7263 *Medicare only

The Assistance Fund: 1-877-245-4412

GoodDays:  877-968-7233

HealthWell Foundation:  800-675-8416 *Medicare only

Patient Advocate Foundation Co-Pay Relief Program: 866-512-3861 *Medicare, Medicaid, Military only

Copay assistance programs frequently open and close due to fluctuating funding levels. If you would like to receive an email or text notification when one of the above copay assistance programs has opened, we suggest using this free tool: Patient Access Network Foundation (PAN) Fund Finder.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The MultipleSclerosis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Join the conversation

or create an account to comment.